Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 9/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 9/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HTR1F | P30939 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22057850 | 0.85 | SMN1; SMN2 (0.36) | HSD11B1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL9103505 | 0.79 | QDPR (0.40) | — | |
| SCHEMBL7833304 | 0.78 | ALOX15 (0.38) | KDM4ELMNAALOX15HTR1FDRD2 | |
| SCHEMBL12574593 | 0.78 | ALDH1A1 (0.47) | LMNASIGMAR1DRD2DRD4 | |
| SCHEMBL13262133 | 0.77 | KDM4E (0.40) | KDM4ELMNAALOX15HTR1FDRD2 | |
| Hydrochloric Acid SCHEMBL11084396 | 0.77 | QDPR (0.39) | — | |
| SCHEMBL13804029 | 0.75 | LMNA (0.36) | HSD11B1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL22057852 | 0.75 | KCNH2 (0.37) | CHRM1KDM4ELMNAALOX15 | |
| SCHEMBL22057224 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL1399926 | 0.74 | LMNA (0.38) | HSD11B1CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103443076-A | Indol-2-one derivatives disubstituted in position 3, their preparation and their therapeutic application | SANOFI AVENTIS | 2013-12-11 | — | — | CN | disclosed |
| US-8202871-B2 | Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-06-19 | — | — | US | disclosed |
| US-20110118280-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20100210662-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210662-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | IDO2, IDO1, TPH2 | HSD11B1 395/4885CHRM2 795/4885CHRM4 1505/4885 |
| US-20110118280-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | IDO2, IDO1, TPH2 | HSD11B1 395/4885CHRM2 795/4885CHRM4 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.